Drug Trial Radar · NCT04923893
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
743
Actual
Start
Aug 19, 2021
Primary completion
Feb 14, 2029
Study completion Sep 22, 2036
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS).
Conditions
- Multiple Myeloma
Interventions
BortezomibDrug
Bortezomib will be administered SC.
DexamethasoneDrug
Dexamethasone will be administered orally.
LenalidomideDrug
Lenalidomide will be administered orally.
Cilta-celDrug
Cilta-cel infusion will be administered.
CyclophosphamideDrug
Cyclophosphamide will be administered intravenously.
FludarabineDrug
Fludarabine will be administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Up to 4 years and 5 months
Locations
136 sites in 26 countries. Site status is shown where the registry gives one.
UCSF
San Francisco, California
Yale Cancer Center
New Haven, Connecticut
University of Miami Health System
Miami, Florida
AdventHealth Cancer Institute
Orlando, Florida
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kentucky
Lexington, Kentucky
Norton Cancer Institute
Louisville, Kentucky
University Of Maryland Medical Center
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Henry Ford Cancer Institute
Detroit, Michigan
Columbia University Medical Center
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
New York Presbyterian-Weill Cornell Medical College
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
Thomas Jefferson University
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
University of Virginia
Charlottesville, Virginia
Medical College Of Wisconsin
Milwaukee, Wisconsin
Hospital Aleman
Buenos Aires, Argentina
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
Hospital Privado Universitario De Cordoba
Córdoba, Argentina
Royal Prince Alfred Hospital
Camperdown, Australia
St Vincents Hospital Melbourne
Fitzroy, Australia
Austin Health
Heidelberg, Australia
Royal Brisbane and Womens Hospital
Herston, Australia
Alfred Health
Melbourne, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Fiona Stanley Hospital
Murdoch, Australia
Calvary Mater Newcastle Hospital
Waratah, Australia
Western Sydney Local Health District
Westmead, Australia
Medizinische Universitat Graz, LKH-Univ.Klinikum Graz, Klinische Abteilung für Hämatologie
Graz, Austria
Krankenhaus der Elisabethinen Linz
Linz, Austria
LKH - Universitätsklinikum der PMU Salzburg
Salzburg, Austria
Medical University of Vienna Universitatsklinik fur Innere Medizin I
Vienna, Austria
Universitair Ziekenhuis - Antwerpen
Antwerp, Belgium
AZ St.-Jan Brugge-Oostende AV
Bruges, Belgium
UZ Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
Liège, Belgium
Showing 40 of 136 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.